Highest-materiality recent filing
Waters announces resignation of SVP Analytical Sciences; Tina Wu to succeed
Robert L. Carpio III resigns as SVP, Waters Analytical Sciences Division, effective Aug 20, 2026, to pursue other opportunities.
Waters Q2 revenue $1.645B beats guidance; raises full-year EPS and revenue outlook
Total revenue $1.645B; organic revenue $828M (+9% constant currency) and acquired business revenue $817M.
Waters shareholders re-elect all 11 directors, ratify PwC, approve say-on-pay at annual meeting
Approx. 90.7M shares (92.4% of eligible) voted at May 21, 2026 annual meeting.
Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60
Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).
Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL
Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.
Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M
Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.
Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions
Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.
Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026
Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.
Waters supplements merger proxy after two stockholder lawsuits alleging omissions
Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.
Waters furnishes investor presentation at J.P. Morgan Conference; no financial details in excerpt
Filing furnishes investor presentation dated January 12, 2026 for J.P. Morgan Healthcare Conference.
Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance
Sales $800M, +8% as reported and constant currency, above guidance.
Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance
Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.
Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal
Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.
Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust
Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.
Waters Corp amends credit facility; removes $200M term loan, retains $1.8B revolver through 2030
Removed existing $200M term loan; retained $1.8B senior unsecured revolving credit facility maturing May 22, 2030.
Waters Corp annual meeting elects all 10 directors, approves compensation and ESPP amendment
Approximately 94.12% of shares represented; all 10 director nominees re-elected.
Waters Q1 2025 results announced; financial details not disclosed in excerpt
Quarter ended March 29, 2025 results released May 6, 2025.
Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00
Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.
Waters to present at J.P. Morgan Healthcare Conference on Jan 13, 2025
CEO Udit Batra will present at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.
Waters appoints Heather Knight to Nominating and Corporate Governance Committee
Heather Knight was appointed to the Board effective August 14, 2024 per prior 8-K.
Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance
Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.
Waters Corporation appoints Heather Knight to Board of Directors
Appointed Heather Knight effective Aug 14, 2024; Board size increased from 9 to 10.
Waters reports Q2 2024 results; full financial details unavailable from excerpt
Press release announces results for the quarter ended June 29, 2024, but full text is not provided.
Waters Corp enters $200M private shelf note facility with NYL Investors
Up to $200M senior promissory notes; maturity up to 15 years per issuance.
Quorum of 54.3M shares (91.63%) present; all 9 director nominees elected with votes ranging from 41.8M to 52.4M for.
Waters Corp reports Q1 2024 results; press release text truncated, no specifics available
Company announced Q1 2024 results on May 7, 2024, but the attached press release text is incomplete.
Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%
Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.
Waters provides J.P. Morgan conference deck; no detailed financials in filing
CEO Udit Batra presented at J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024.
Waters announces Q3 2023 results; details missing from filing excerpt
Waters Corporation reported results for quarter ended Sep 30, 2023 on Nov 7, 2023.
Waters Corp: SVP Jonathan Pratt resigns; Christos Ross named interim successor
Jonathan Pratt resigns as SVP of Waters Division effective Oct 24 to pursue external opportunity.
Waters Q2 sales up 4% to $741M, non-GAAP EPS $2.80; lowers FY organic growth guide to 0.5-1.5%
Pharmaceutical market sales down 4% organic CC; China sales declined high teens.
Waters re-elects all 9 directors, ratifies PwC, and approves say-on-pay at annual meeting
All 9 director nominees re-elected; votes ranged from 42.1M (Ornskov) to 49.7M (Batra, Brennan) for.
Waters completes $1.36B cash acquisition of Wyatt Technology
Total purchase price of $1.36B in cash, financed via balance sheet and credit facility.
Waters Corp issues $100M in 4.91% senior notes; establishes $400M private shelf facility
Issued $50M Series P 4.91% notes due 2028 and $50M Series Q 4.91% notes due 2030 to PGIM and purchasers.
Waters Q1 sales down 1% to $685M, non-GAAP EPS $2.49; guides FY organic growth 3-5%
Q1 sales $685M (-1% reported, +3% constant currency); GAAP EPS $2.38, non-GAAP EPS $2.49, both down YoY.
Waters appoints Richard Fearon (ex-Eaton VP/CFO) to Board; size increased to 10
Richard Fearon appointed effective March 27, 2023, filling a new vacancy; Board expanded from 9 to 10 members.
Waters Corp increases revolving credit facility by $200M to $2.0B, transitions to Term SOFR
Revolving facility increased by $200 million to aggregate $2.0 billion.
Waters to acquire Wyatt Technology for $1.36B cash; Q4 revenue up 9% CC, EPS beat
Acquisition of Wyatt Technology for $1.36B cash, expected to close Q2 2023.
Waters presents at J.P. Morgan Healthcare Conference; no specific financial updates in filing
CEO Udit Batra presented at J.P. Morgan 41st Annual Healthcare Conference on Jan 9, 2023.
Waters Corp assigns new directors to Audit and Nominating committees
Dan Brennan appointed to Audit Committee effective December 13, 2022.
Waters Corp appoints Dan Brennan and Mark Vergnano to Board of Directors
Board expanded from 7 to 9 members; appointments effective November 23, 2022.
Waters Q3 sales $709M (+7% reported, +15% cc); raises FY22 sales guidance
GAAP EPS $2.60 flat YoY; non-GAAP EPS $2.64 vs $2.66 (FX headwind ~13%).
Waters Q2 sales $714M +10% cc, GAAP EPS $2.72, non-GAAP $2.75; raises FY sales guidance to 9.5-10.5%
Q2 sales $714M (+5% as reported, +10% constant currency); instrument sales +12% cc, recurring +8% cc.
Waters shareholders re-elect all 8 directors, ratify PwC, approve say-on-pay at annual meeting
All 8 director nominees elected; votes ranged from 46.9M (Ornskov) to 53.2M (Jiang) in favor.
Waters holds 2022 Investor Day; reiterates prior guidance, no new financials
Held Investor Day on May 19, 2022 at NYSE with live webcast; presentation covers historical performance, strategy, and outlook.
Waters reports Q1 2022 results; financial details not extractable from filing
Filed results for quarter ended April 2, 2022 via press release Exhibit 99.1.
Waters director John Ballbach resigns from board effective March 30, 2022
John Ballbach resigned from the Waters Corporation Board of Directors on March 30, 2022.
Waters announces Q4 and full year 2021 results; details not available from provided filing text
Press release referenced as Exhibit 99.1 but full text not included in filing excerpt.
Waters presents at J.P. Morgan Healthcare Conference, details not in filing
Investor presentation furnished as Exhibit 99.1 for J.P. Morgan Healthcare Conference on Jan 10, 2022.
On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.
On October 18, 2023, Jonathan Pratt notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President of the Waters Division, effective October 24, 2023.
On March 27, 2023, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Richard Fearon to the Board, effective March 27, 2023, to fill the vacancy so created.
appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022
appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022
On July 28, 2022, Thomas Salice notified the Company of his decision to retire from the Board of Directors (the “Board”) as of such date.
On March 30, 2022, John Ballbach resigned from the Board of Directors (the “Board”) of Waters Corporation, effective as of such date.
On October 1, 2021, Dr. Michael Berendt notified the Board of Directors (the “Board”) of Waters Corporation (the “Company”) of his decision to retire as director of the Company, including from any committees thereof, such retirement, effective October 5, 2021.
On October 5, 2021, the Board appointed John M. Ballbach to the Board, effective October 5, 2021, to fill the vacancy left by Dr. Berendt’s retirement.
Max materiality 0.90 · Median 0.50 · Most common event earnings